Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma
Open Access
- 4 August 2007
- journal article
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 5 (1) , 89
Abstract
Malignant gliomas recur even after extensive surgery and chemo-radiotherapy. Although a relatively novel chemotherapeutic agent, temozolomide (TMZ), has demonstrated promising activity against recurrent glioma, the effects last only a few months and drug resistance develops thereafter in most cases. Induction of O6-methylguanine-DNA methyltransferase (MGMT) in tumors is considered to be responsible for resistance to TMZ. Interferon-beta has been reported to suppress MGMT in an experimental glioma model. Here we report a patient with TMZ-refractory anaplastic astrocytoma (AA) who was treated successfully with a combination of interferon-beta and TMZ.Keywords
This publication has 21 references indexed in Scilit:
- Potentiation of antiglioma effect with combined temozolomide and interferon-βOncology Reports, 2006
- Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)British Journal of Cancer, 2006
- A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiformeJournal of Neuro-Oncology, 2006
- [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study].2006
- IFN-β Down-Regulates the Expression of DNA Repair Gene MGMT and Sensitizes Resistant Glioma Cells to TemozolomideCancer Research, 2005
- Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic GliomasClinical Cancer Research, 2005
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastomaNeurology, 2004
- Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapseAnnals of Oncology, 2001
- Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First RelapseJournal of Clinical Oncology, 1999